Email not displaying correctly? View it in your browser
Forward to a colleague | Sign up to BNF eNews
BNF BNF for Children Medicines Complete
March 2018 Share this issue Facebook LinkedIn Twitter
 
I Welcome
Welcome to the March BNF eNewsletter.
This month sees the publication of the new BNF 75. Read on for more details and to order your copies now!

Three new drug monographs have been added to the BNF in the last month: guselkumab, niraparib, and tenofovir alafenamide.

This issue includes dose changes for adalimumab, budesonide, chloroquine, and gentamicin, as well as updated guidance on the management of attention deficit hyperactivity disorder, emergency contraception, and urinary tract infections in children. We have included updated MHRA advice on daclizumab and the risk of severe liver injury, and advice about the very rare risk of severe cutaneous adverse reactions with recombinant human erythropoietins. You will also find NICE technology appraisals for naltrexone-bupropion for managing overweight and obesity, and cladribine tablets for treating relapsing-remitting multiple sclerosis.
Kind regards,
BNF Team
I In this issue
BNF 75 available More >  
Significant changes More >  
News More >  
How to purchase BNF More >  
Drug safety update More >  
Feedback More >  
BNF BNF 75 available to order now!
The new British National Formulary 75 (BNF) is now available, compiled to give you with the latest guidance on prescribing, dispensing, and administering medicines. This updated edition continues to reflect current best practice as well as legal and professional guidelines relating to the uses of medicines.

With the formally NICE accredited editorial process and access to new monographs and advice, dosage & safety information, the latest edition of the BNF is vital for all healthcare professionals.

Find out more and get your copy of BNF 75 here!

New content updates include:
New guidance on premature ejaculation and spondyloarthritis.
Updated guidance for acute porphyrias, breast cancer (chemoprevention and management of menopausal symptoms), controlled drugs and drug dependence, prevention of neural tube defects in pregnancy, non-medical prescribing, Parkinson’s disease, and diabetes in pregnancy and breast-feeding.
New drug monographs including alectinib, brodalumab, eliglustat, migalastat, sarilumab, ribociclib, obeticholic acid, and tofacitinib.
New safety information on daclizumab and the risk of severe liver injury, and gabapentin and the risk of severe respiratory depression.
Updated advice on the use of pemetrexed for the maintenance treatment of non-small-cell lung cancer.
 
Significant dose changes including ibrutinib dose adjustments due to interactions and anastrozole, tamoxifen and raloxifene for chemoprevention of breast cancer [unlicensed use].
BNF 75

ISBN: 978 0 8571 1331 3
March 2018 • Paperback • 1,600pp

I Significant
changes
This month's changes to the clinical content of these publications are described in three parts:

BNF and BNFC update should be read by all users
BNF update should be read by all users of the BNF
BNFC update should be read by all users of the BNF for Children
BNF 72 - BNFC 2016-2017
BNF Update
Guselkumab: new drug monograph
For further information, see guselkumab.
Niraparib: new drug monograph
For further information, see niraparib.
Daclizumab (Zinbryta®) and risk of severe liver injury: new restrictions to use and strengthened liver monitoring (MHRA advice)
For further information, see daclizumab.
Dose changes
Budesonide [alternative dosing regimen for Crohn’s disease updated for Budenofalk® capsules]
For further information, see budesonide.
Chloroquine [clarification of dosing for rheumatoid arthritis, systemic and discoid lupus erythematosus]
For further information, see chloroquine.
Olaparib [dose in renal impairment]
For further information, see olaparib.
NICE technology appraisal update:
NICE technology appraisals that have been added to the BNF this month include:
Cladribine tablets for treating relapsing-remitting multiple sclerosis
Naltrexone-bupropion for managing overweight and obesity
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2- negative, locally advanced or metastatic breast cancer
Other changes
To review other changes in the BNF, click on changes.
BNF for Children Update
Guidance on prescribing: updated guidance on multimorbidity and deprescribing
For further information, see guidance on prescribing.
Urinary tract infections: updated guidance on management
For further information, see urinary tract infections.
Dose changes
Adalimumab [doses for plaque psoriasis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis]
For further information, see adalimumab.
Other changes
To review other changes in BNF for Children, click on changes.
BNF BNF for Children Update
Tenofovir alafenamide: new drug monograph
For further information, see tenofovir alafenamide.
Recombinant human erythropoietins (epoetin alfa, epoetin beta, epoetin zeta, darbepoetin alfa, methoxy polyethylene glycol-epoetin): very rare risk of severe cutaneous adverse reactions (MHRA advice)
For further information, see relevant drug monographs.
Drug name confusion: reminder to be vigilant for potential errors between clobazam and clonazepam, atenolol and amlodipine, propranolol and prednisolone, risperidone and ropinirole, sulfadiazine and sulfasalazine, amlodipine and nimodipine, mercaptamine and mercaptopurine, zuclopentixol acetate and zuclopentixol decanoate (MHRA advice)
For further information, see relevant drug monographs.
Attention deficit hyperactivity disorder: updated guidance on management
For further information, see attention deficit hyperactivity disorder.
Emergency contraception: updated guidance on management
For further information, see attention deficit hyperactivity disorder.
Dose changes
Tramadol with paracetamol [clarification of dosing]
For further information, see tramadol with paracetamol.
Chloroquine [clarification of dose equivalence statement]
For further information, see chloroquine.
I News
Reminder - help from CPPE with BNF 74
An interactive PDF e-learning programme from the Centre for Pharmacy Postgraduate Education (CPPE) will help you familiarise yourself with recommendations in BNF 74. It comprises 10 practical case studies that help you keep up to date with recent changes in the BNF, and can be accessed here.
BNF 74
I How to purchase BNF
Purchase Print copies
Purchase print copies
To order the March 2018 edition, visit the Pharmaceutical Press website.
More
Purchase a print subscription
Purchase a print subscription and save money
A print subscription is the best way to ensure access to the latest copy of BNF as soon as it publishes.
More
BNF online
BNF online
Outside the UK, content is available via a subscription to MedicinesComplete.
Email us
BNF eBook
BNF eBook
BNF is also available as a PDF eBook.
More
Drug Safety Update
Drug Safety Update is a monthly newsletter from
the MHRA and Commission on Human Medicine.
Please follow this link to review this month's Drug Safety Update.
I Feedback on our eNewsletter
Please let us know if there are any issues that you'd like us to address in our eNewsletters. We welcome your feedback. If you have any comments or suggestions, please let us know at marketing@rpharms.com.
Subscribe to this eNewsletter here
I Related Products
Medicines Complete BNF Pharmaceutical Press
BNF
Copyright © 2018 BMJ Publishing Group Ltd and the Royal Pharmaceutical Society of Great Britain. All rights reserved. Terms of use.
BNF for Children
Copyright © 2018 BMJ Publishing Group Ltd, the Royal Pharmaceutical Society of Great Britain and RCPCH Publications. All rights reserved. Terms of use.
If you do not wish to receive such mailings in the future please click here to unsubscribe.
Pharmaceutical Press, 66-68 East Smithfield, London, E1W 1AW, United Kingdom.